IRLAB Therapeutics AB Class A (SE:IRLAB.A)
:IRLAB.A
Want to see SE:IRLAB.A full AI Analyst Report?
Top Page
IRLAB Therapeutics AB Class A
(IRLAB.A)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr1.00
▼(-50.25% Downside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by persistent losses and significant ongoing cash burn, which increases funding risk despite improved revenue. Technicals also weaken the outlook, with the stock trading below all major moving averages and negative MACD. Valuation is modestly supportive due to a low P/E, but it is not enough to offset the financial and trend risks.
Positive Factors
Revenue Recovery
Sustained, material revenue rebound (+60.9% TTM) indicates improving commercial or collaboration traction and stronger top-line momentum. Over 2-6 months this supports continued program funding, validates demand for assets, and improves prospects for partnerships or staged financing.
Negative Factors
High Cash Burn
Sustained ~-90M TTM operating and free cash flow creates chronic funding pressure. Over the medium term the company likely needs new capital to run trials, increasing dilution or debt risk and constraining ability to scale development without external partners or financings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
Sustained, material revenue rebound (+60.9% TTM) indicates improving commercial or collaboration traction and stronger top-line momentum. Over 2-6 months this supports continued program funding, validates demand for assets, and improves prospects for partnerships or staged financing.
Read all positive factors
IRLAB Therapeutics AB Class A (IRLAB.A) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr109.40M
Dividend YieldN/A
Average Volume (3M)244.46K
Price to Earnings (P/E)3.4
Beta (1Y)0.36
Revenue Growth-6.59%
EPS Growth27.05%
CountrySE
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.04
Shares Outstanding84,858,246
10 Day Avg. Volume145,848
30 Day Avg. Volume244,458
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)4.30
Price to Sales (P/S)2.30
P/FCF Ratio-2.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.62
Revenue Forecast (FY)kr96.90M
IRLAB Therapeutics AB Class A Business Overview & Revenue Model
Company Description
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial fo...
How the Company Makes Money
null...
IRLAB Therapeutics AB Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 92.46M | 57.46M | 94.63M | 5.68M | 61.14M | 207.78M |
| Gross Profit | -39.73M | -92.35M | -92.42M | -122.73M | -111.23M | 168.69M |
| EBITDA | -48.79M | -88.03M | -68.07M | -173.32M | -109.13M | 55.79M |
| Net Income | -66.92M | -110.01M | -83.13M | -177.84M | -114.20M | 51.78M |
Balance Sheet | ||||||
| Total Assets | 135.03M | 138.21M | 136.21M | 177.12M | 323.56M | 472.45M |
| Cash, Cash Equivalents and Short-Term Investments | 50.79M | 81.86M | 66.92M | 111.31M | 252.78M | 401.90M |
| Total Debt | 27.08M | 29.95M | 60.42M | 27.57M | 3.98M | 6.60M |
| Total Liabilities | 95.19M | 107.49M | 103.58M | 61.36M | 32.72M | 72.97M |
| Stockholders Equity | 39.84M | 30.72M | 32.63M | 115.76M | 290.83M | 399.48M |
Cash Flow | ||||||
| Free Cash Flow | -90.23M | -55.22M | -65.79M | -165.14M | -145.99M | 127.93M |
| Operating Cash Flow | -90.23M | -55.22M | -65.59M | -164.85M | -142.61M | 128.64M |
| Investing Cash Flow | 0.00 | 0.00 | -199.00K | -293.00K | -3.38M | -708.00K |
| Financing Cash Flow | 54.19M | 73.41M | 21.40M | 23.68M | -3.13M | -3.04M |
IRLAB Therapeutics AB Class A Technical Analysis
Negative
2.01
Price Trends
1.47
Negative
1.64
Negative
2.15
Negative
Market Momentum
-0.07
Negative
41.38
Neutral
57.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IRLAB.A, the sentiment is Negative. The current price of 2.01 is above the 20-day moving average (MA) of 1.35, above the 50-day MA of 1.47, and below the 200-day MA of 2.15, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 41.38 is Neutral, neither overbought nor oversold. The STOCH value of 57.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IRLAB.A.
IRLAB Therapeutics AB Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr229.79M | -3.65 | -51.35% | ― | ― | 9.40% | |
49 Neutral | kr189.27M | -4.31 | -1291.15% | ― | ― | 49.87% | |
43 Neutral | kr109.40M | 3.37 | -199.86% | ― | -6.59% | 27.05% | |
43 Neutral | kr223.07M | -3.55 | ― | ― | -45.86% | 3.50% | |
42 Neutral | kr204.67M | -3.27 | ― | ― | ― | -58.96% | |
41 Neutral | kr214.77M | -12.73 | -59.78% | ― | ― | 43.30% |
* Healthcare Sector Average
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.29
-5.33
-80.54%
SE:ISOFOL
Isofol Medical AB
0.72
-0.34
-31.91%
SE:XINT
Xintela AB
0.26
-0.22
-45.70%
SE:ELIC
Elicera Therapeutics AB
2.95
-3.35
-53.20%
SE:ACTI
Active Biotech AB
0.07
-0.05
-42.74%
SE:INIT
Initiator Pharma A/S
2.99
-0.72
-19.41%
IRLAB Therapeutics AB Class A Corporate Events
IRLAB boosts finances as LIFT-PD trial starts and milestone cash arrives
May 6, 2026
IRLAB Therapeutics reported that the first patients with Parkinson’s disease and apathy have been dosed in the LIFT-PD clinical study evaluating its drug candidate IRL757, triggering a milestone payment of USD 3 million that helped lift net ...
IRLAB Calls Extraordinary Meeting to Approve Major Share Issues and Governance Changes
May 5, 2026
IRLAB Therapeutics AB has called an extraordinary general meeting for June 5, 2026, in Göteborg, where shareholders will vote on key governance and capital structure measures. The agenda includes amending the Articles of Association to signif...
IRLAB Launches Heavily Backed Rights Issue to Fund Pipeline and Extend Runway
May 5, 2026
IRLAB Therapeutics plans to raise approximately SEK 68 million through a rights issue of series A shares, with an additional SEK 33.8 million available via an overallotment issue, both subject to shareholder approval and changes to the articles of...
IRLAB to Webcast Q1 2026 Results as Parkinson’s Pipeline Advances
Apr 30, 2026
IRLAB Therapeutics will present its interim report for the first quarter of 2026 via a digital webcast on May 6, where the CEO, head of RD, and CFO will comment on the results and take questions in Swedish. The event underlines the company’s...
IRLAB Highlights Broad Parkinson’s Pipeline and Validated R&D Strategy in 2025 Annual Report
Apr 29, 2026
IRLAB’s business centers on a broad and advanced pipeline of five unique drug candidates for Parkinson’s and related CNS conditions, all derived from its ISP research platform and designed to address symptoms and complications througho...
IRLAB strengthens Board with commercialization experts as it advances Parkinson’s pipeline
Apr 17, 2026
IRLAB Therapeutics’ Nomination Committee has proposed significant changes to the Board ahead of the 2026 Annual General Meeting, including the election of Jan-Fredrik Backman as Vice Chairperson and James Gamgort as a new Board member, while...
IRLAB to Showcase Expanding Parkinson’s Pipeline at Redeye Healthcare Day 2026
Apr 9, 2026
IRLAB Therapeutics AB, a Swedish biopharma company specializing in Parkinson’s disease therapies, is preparing several drug candidates across late-stage and early-stage development. Its portfolio spans Mesdopetam, which has completed Phase I...
IRLAB Showcases Parkinson’s Pipeline and AI Discovery Advances at AD/PD 2026
Mar 17, 2026
IRLAB Therapeutics will present new clinical and preclinical data at the AD/PD 2026 conference in Copenhagen, highlighting progress across its Parkinson’s disease pipeline and discovery platform. The company will showcase phase IIb data for ...
IRLAB to Showcase Parkinson’s Pipeline at Gothenburg Life Science Day
Mar 2, 2026
IRLAB Therapeutics AB, a Swedish biotech specializing in innovative Parkinson’s disease therapies, is advancing a diversified pipeline that spans late-stage candidates for levodopa-induced dyskinesias and fall reduction, as well as earlier-s...
IRLAB Triggers USD 3 Million Milestone as First Patient Dosed in IRL757 Parkinson’s Apathy Trial
Feb 26, 2026
IRLAB Therapeutics has dosed the first patient in its Phase Ib LIFT-PD trial of IRL757, a potential treatment for apathy in Parkinson’s disease, triggering a USD 3 million milestone payment from its development partner, the McQuade Center fo...
IRLAB Advances CNS Pipeline as 2025 Loss Widens and Cash Position Strengthens
Feb 25, 2026
IRLAB Therapeutics reported full-year 2025 results showing net sales of SEK 57.5 million, a widened operating loss of SEK 93.4 million and year-end cash of SEK 81.9 million, while maintaining an average of 31 employees and seeing its share price d...
IRLAB Wins Expert Backing to Advance Parkinson’s Drug Pirepemat After Positive Phase IIb Signals
Feb 20, 2026
IRLAB Therapeutics has received unanimous backing from its scientific advisory board to proceed with development of its Parkinson’s candidate pirepemat, after experts judged the pharmacological rationale sound and the reduction in falls seen...
IRLAB to Webcast Year-End 2025 Results as Parkinson’s Pipeline Advances
Feb 18, 2026
IRLAB Therapeutics AB, a Nasdaq Stockholm-listed biopharmaceutical developer of novel Parkinson’s disease treatments, will publish its year-end 2025 report on February 25, 2026, at 07:00 CET. The Gothenburg-based company, led by CEO Kristina...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.